Cancer, Lung Clinical Trial
Official title:
The Effect of Oral Nutrition Supplement Formulas (ONS) and Diet Counseling on Improvement of Nutritional Status, Knowledge, Attitudes, and Behavior of Cancer Patients
The goal of this clinical trial is to evaluate the efficacy oral nutrition supplement (ONS) in malnutrition/high risk malnutrition cancer patients. The main questions it aims to answer: 1. Are there differences in knowledge, attitude and behaviour scores in cancer patients who receive cancer-specific ONS compared to those who do not receive cancer-specific ONS? 2. Is there a difference in nutritional status as assessed by average body weight, body mass index (BMI), haemoglobin (Hb), and albumin levels in cancer patients who receive cancer-specific ONS compared to those who do not receive cancer-specific ONS?
Status | Recruiting |
Enrollment | 80 |
Est. completion date | February 28, 2024 |
Est. primary completion date | November 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically confirmed lung and ob-gyn cancer patients (who have not undergone therapy or are currently undergoing therapy) - Aged greater than or equal to 18 years - Patients with a performance status score of 0 - 2 - Have inadequate food intake >5 days or: 1. BMI/body mass index <18.5 kg/m2 or 2. There is a >10% weight loss in the last 3-6 months or 3. BMI <20 kg/m2 or 4. There is >5% weight loss in the last 3-6 months with - Intervention group subjects are willing to take ONS orally for 8 weeks - Intervention group subjects, if they have taken other brands of ONS, are willing to stop taking ONS 2 weeks prior to the study. Exclusion Criteria: - Pregnant and breastfeeding, except for female subjects with one of the following criteria: 1. Have a history of hysterectomy (surgical removal of the uterus) and/or bilateral oophorectomy (surgical removal of the ovaries). 2. Medically confirmed ovarian failure (decreased ovarian function) 3. Achieved post menopausal status, defined as: cessation of regular menstruation for at least 12 consecutive months in the absence of pathological or physiological causes. - Renal insufficiency (eGFR ( Estimated Glomerular Filtration Rate ) <15 mL/min/1.73 m2 or significant increase in urea/creatinine or having to be on a low protein diet) - Liver insufficiency (SGOT (Serum Glutamic Oxaloacetic Transaminase) /SGPT (Serum Glutamic Pyruvic Transaminase) values =3 times the normal limit) |
Country | Name | City | State |
---|---|---|---|
Indonesia | Persahabatan Hospital | Jakarta |
Lead Sponsor | Collaborator |
---|---|
Kalbe International Pte. Ltd | Persahabatan Hospital |
Indonesia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Nutrition consumption knowledge score | To determine changes in nutrition consumption knowledge scores in cancer patients who received cancer-specific ONS compared to those who did not receive ONS after 8 weeks of intervention using questioner .
Interpretation Knowledge score (5 questions): good (score>=8 ) moderate (score 5-8) poor (score 0-4); |
8 weeks | |
Primary | Nutrition consumption attitude score | To determine changes in nutrition consumption attitudes score in cancer patients who received cancer-specific ONS compared to those who did not receive ONS after 8 weeks of intervention using questioner .
Interpretation Attitude score (10 questions): good (score>=30 ) moderate (score 21-30) poor (score 0-20) |
8 weeks | |
Primary | Nutrition consumption behaviour score | To determine changes in nutrition consumption behavior in cancer patients who received cancer-specific ONS compared to those who did not receive ONS after 8 weeks of intervention using questioner .
Interpretation Behaviour score(10 questions): good (score>=30 ) moderate (score 21-30) poor (score 0-20). |
8 weeks | |
Primary | Nutritional status by body weight | To determine changes in BW (body weight in kg) in cancer patients who received cancer-specific ONS compared to those who did not receive ONS after the 8-week intervention. The higher the increase in BW, the better. | 8 weeks | |
Primary | Nutritional status by body mass index | To determine changes in BMI (body mass index in kg/m2) in cancer patients who received cancer-specific ONS compared to those who did not receive ONS after the 8-week intervention. The higher the increase in BMI, the better.
BMI is calculated as weight in kilograms divided by the square of the height in meters (kg/m2) and is categorized into four groups according to the cutoff points: underweight (<18.5 kg/m2), normal weight (18.5-22.9 kg/m2), overweight (23-24.9 kg/m2), obese grade 1 (=25-29 kg/m2) and obese grade 2 (>29 kg/m2) |
8 weeks | |
Primary | Nutritional status by haemoglobin | To determine changes in Hb (haemoglobin in mg/dL) level in cancer patients who received cancer-specific ONS compared to those who did not receive ONS after the 8-week intervention. The higher the increase in haemoglobin level, the better. | 8 weeks | |
Primary | Nutritional status by albumin | To determine changes in Albumin level (g/dL) in cancer patients who received cancer-specific ONS compared to those who did not receive ONS after the 8-week intervention. The higher the increase in albumin level, the better | 8 weeks | |
Secondary | Calorie intake | Changes in calorie intake between ONS group vs control group after an 8-week intervention. Assessment of calorie intake using NutriSurvey 2007, Food Recall 2x24h & Food Record 3x24h. The higher subject's calorie (kcal) intake ,the better. | 8 weeks | |
Secondary | Protein intake | Changes in protein intake between ONS group vs control group after an 8-week intervention. Assessment of protein intake using NutriSurvey 2007, Food Recall 2x24h & Food Record 3x24h. The higher subject's protein (gram) intake ,the better | 8 weeks | |
Secondary | Quality of life with QLC-30 score | The change in quality of life between ONS group vs control group; assessed by QLC-C30 (Quality of Life Questionnaire Core-30) score after 8 weeks of intervention. QLC-C30 is a 30 item instrument meant to assess some of the different aspects that define the quality of life of cancer patients.
Interpretation of QLC-C30 score: a.Good =1000 b.Moderate = 500-1000 c.Poor =500 |
8 weeks | |
Secondary | Inflammatory status by CRP | The change in inflammatory status between ONS group vs control group assessed by CRP(C-reactive protein in mg/L) level (using CRP Latex Kit) after the 8-week intervention. The lower the value of CRP, the better. | 8 weeks | |
Secondary | Inflammatory status by IL-1 | The change in inflammatory status between ONS group vs control group assessed by IL-1 (interleukin-1 in pg/ml) level (using IL-1 ELISA kit) after the 8-week intervention The lower the value of IL-1, the better. | 8 weeks | |
Secondary | Inflammatory status by IL-6 | The change in inflammatory status between ONS group vs control group assessed by IL-6 (interleukin-6 in pg/ml) level (using IL-6 ELISA kit) after the 8-week intervention. The lower the value of IL-6, the better. | 8 weeks | |
Secondary | Inflammatory status by TNF-a | The change in inflammatory status between ONS group vs control group assessed by TNF-a (Tumor necrosis factor alpha in pg/ml) level (using Kit Quantikine ELISA Human TNF- a) after the 8-week intervention. The lower the value of TNF-a, the better. | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06152419 -
Patient Education Videos to Improve Patients' Experience During Radiotherapy Treatment: a National Project
|
N/A | |
Recruiting |
NCT04105647 -
Lifestyle Modification Program for Lung Cancer Patients - A Pilot Study
|
N/A | |
Completed |
NCT05732350 -
Exploratory Drug Interaction Study Between SMIs and DOACs
|
||
Active, not recruiting |
NCT04300244 -
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
|
Phase 2 | |
Recruiting |
NCT05311709 -
Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities
|
Phase 2 | |
Active, not recruiting |
NCT04396457 -
Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901
|
Phase 2 | |
Recruiting |
NCT06391749 -
Clinical Validation of an MCED Test in Symptomatic Populations (K-ACCELERATE)
|
||
Not yet recruiting |
NCT03910283 -
Leveraging Mindsets to Improve Health & Wellbeing in Patients With Cancer
|
N/A | |
Recruiting |
NCT03301493 -
Genomic Testing and Resulting Medical Decisions
|
||
Completed |
NCT04788147 -
Performance and Safety of Biology-Guided Radiotherapy Using the RefleXion Medical Radiotherapy System (BIOGUIDE-X)
|
N/A | |
Not yet recruiting |
NCT06035731 -
Evaluation of the Medical Service by Socio-aesthetics in Oncology
|
N/A | |
Recruiting |
NCT03274349 -
Whole Body Electromyostimulation and Nutritional Therapy for Patients With Esophageal and Bronchial Carcinoma
|
N/A | |
Recruiting |
NCT05830097 -
A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02991677 -
Exercise Effect on Chemotherapy-Induced Neuropathic Pain
|
N/A | |
Completed |
NCT04971304 -
Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars
|
||
Recruiting |
NCT04859400 -
Influence of a Home-based Nutrition and Exercise Program on Quality of Life of Palliative Cancer Outpatients
|
N/A | |
Recruiting |
NCT05948865 -
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04270890 -
Investigation of an Abdominal Compression Device
|
N/A | |
Not yet recruiting |
NCT05154474 -
Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy
|
||
Not yet recruiting |
NCT05857995 -
Precision Lung Cancer Survivorship Care Intervention
|
N/A |